rs1746048 — CXCL12

CXCL12 — The Chemokine That Guides Inflammatory Cells Into Coronary Arteries

Beneath the surface of every coronary artery, a biochemical signaling system continuously directs immune cells to sites of injury and repair. At the center of this system is CXCL12¹¹ CXCL12
C-X-C motif chemokine ligand 12, also known as stromal cell-derived factor 1 (SDF-1), a chemokine that acts as a powerful attractant for progenitor cells, natural killer cells, and immune progenitors via its receptor CXCR4. The rs1746048 variant lies approximately 80 kilobases downstream of the CXCL12 gene on chromosome 10q11.21 and is one of the earliest and most consistently replicated genome-wide significant loci for coronary artery disease (CAD). It was among the first loci to reach genome-wide significance in large GWAS meta-analyses and has been replicated across European, East Asian, and South Asian populations.

The Mechanism

The rs1746048 variant does not alter the CXCL12 protein directly. It is an intergenic regulatory variant that modulates how much CXCL12 protein circulates in the bloodstream. Carriers of the risk C allele have demonstrably higher plasma CXCL12 levels than T allele carriers. Mehta et al. (2011)²² Mehta et al. (2011)
The novel atherosclerosis locus at 10q11 regulates plasma CXCL12 levels, Eur Heart J 2011 showed a dose-dependent relationship: CC carriers had the highest CXCL12 levels, CT intermediate, and TT the lowest (2.33 vs 2.27 vs 2.21 ng/mL, P=0.034), and identified elevated CXCL12 transcript expression in natural killer cells and liver tissue as the downstream effectors.

Elevated CXCL12 promotes atherosclerosis through several mechanisms: it accelerates the migration and retention of hematopoietic progenitor cells³³ hematopoietic progenitor cells
bone marrow-derived precursor cells including monocyte precursors into arterial walls, increases the homing of inflammatory immune cells to developing plaques, and drives neovascularization⁴⁴ neovascularization
formation of new blood vessels within plaques, which are structurally fragile and prone to hemorrhage of atherosclerotic lesions. Additionally, a 2017 Pakistani study found that the C risk allele is associated with elevated IL-18 and a higher IL-18:IL-10 pro-inflammatory ratio, pointing toward dysregulated cytokine balance as a downstream consequence of elevated CXCL12 signaling.

The variant's effect on carotid intima-media thickness — a direct measure of subclinical atherosclerosis — has been quantified. A 2015 meta-analysis found that each C allele is associated with approximately 0.008 mm thicker carotid walls, suggesting the variant promotes vascular remodeling independent of established lipid risk factors.

The Evidence

The evidence base for rs1746048 is substantial and unusually consistent across ethnic groups. The most comprehensive meta-analysis, Chen et al. (2017)⁵⁵ Chen et al. (2017)
Meta-analysis pooling 48,852 CHD patients and 64,386 controls from 12 studies, Medicine (Baltimore), found per-C-allele odds ratios of 1.07 in Asian populations and 1.14 in Caucasian populations (1.11 overall). A concurrent meta-analysis by Huang et al. (2013)⁶⁶ Huang et al. (2013)
Case-control study in Han Chinese plus meta-analysis of >107,000 individuals, Gene confirmed an OR of 1.12 (P<0.0001), with subgroup analysis showing the effect is amplified in older patients (OR 1.91 for age ≥65) and males under a recessive model (OR 1.72 for CC+CT vs TT).

The longitudinal evidence is equally convincing. Wirtwein et al. (2017)⁷⁷ Wirtwein et al. (2017)
1,345 confirmed CAD patients with 8.6-year follow-up, Int J Cardiol showed that rs1746048 predicted both the need for revascularization procedures and major adverse cardiovascular events (MACE), indicating that the variant does not merely associate with incident CAD but also with its clinical severity and progression over time.

Practical Actions

The rs1746048 C allele is common — approximately 68% of people globally carry CC. Its per-allele effect is modest (OR ~1.12 per C allele), but it is one of the more robustly replicated GWAS hits for CAD, and its effect through elevated CXCL12 levels means it operates through an inflammatory pathway distinct from the standard lipid-driven mechanisms targeted by statins.

The T allele is protective and dose-dependent: CT carriers have measurably lower plasma CXCL12 levels and modestly lower CAD risk than CC carriers, and TT homozygotes have the lowest CXCL12 levels of all. For CC homozygotes, the key clinical implication is earlier subclinical atherosclerosis screening — particularly carotid intima-media thickness measurement and coronary artery calcium scoring — since the mechanistic evidence points directly to arterial wall thickening as a downstream effect.

Interactions

The strongest documented interaction is with rs501120, a neighboring variant also on chromosome 10q11.21 and also downstream of CXCL12. Mehta et al. showed that rs1746048 and rs501120 are both independently associated with CAD risk and both regulate plasma CXCL12 levels, suggesting that the 10q11.21 locus contains multiple functional regulatory elements rather than a single causal variant. Combined genotype data for these two SNPs has not been formally analyzed in a compound heterozygosity framework.

rs1746048 also co-occurs in multi-locus CAD genetic risk scores alongside rs4977574 (CDKN2B-AS1 / 9p21 locus) and rs1333049 (another 9p21 variant). The 9p21 locus and the 10q11.21 locus operate through distinct mechanisms — cell cycle regulation versus chemokine-driven inflammation respectively — meaning that carrying risk alleles at both loci compounds risk through non-overlapping biological pathways.